Barely Significant
← all excerpts

Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.

J Patient Rep Outcomes · 2023 · PMC10656371 · PMID 37975967

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
Similar to the findings from the ER analysis from the original NDA, the ER analysis using PR-diarrhea assessed by PRO-CTCAE showed a trend of increasing probability of diarrhea (LWS ≥ 3) frequency with increasing steady state exposure (AUCs) (Fig. 2 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.